Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]-and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909). 1996

D Matecka, and R B Rothman, and L Radesca, and B R de Costa, and C M Dersch, and J S Partilla, and A Pert, and J R Glowa, and F H Wojnicki, and K C Rice
Laboratory of Medicinal Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.

The design, synthesis, and biological evaluation of compounds related to the dopamine (DA) uptake inhibitors: 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine (1) and 1-[2-[bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (2) (GBR 12395 and GBR 12909, respectively), directed toward the development and identification of new ligands interacting with high potency and selectivity at the dopamine transporter (DAT) is reported. The substitution of the piperazine ring in the GBR structure with other diamine moieties resulted in the retention of the high affinity of new ligands for the DAT. Some of the modified GBR analogs (e.g. 8, 10, (-)-49, or (-)-50) displayed substantially higher selectivity (4736- to 693-fold) for the dopamine (DA) versus the serotonin (5HT) reuptake site than the parent compounds. The bis(p-fluoro) substitution in the (diphenylmethoxy)ethyl fragment slightly increased the affinity of the ligands at the DA reuptake site but reduced their selectivity at this site (e.g. 9 and 8, 11 and 10, or 17 and 16, respectively). Congeners, such as the series of monosubstituted and symmetrically disubstituted piperazines and trans-2,5-dimethylpiperazines, which lack the (diphenylmethoxy)ethyl substituent lost the affinity for the DAT yet exhibited very high potency for binding to the sigma receptors (e.g.28). The chiral pyrrolidine derivatives of 1, (-)-49, and (+)-49, exhibited an enantioselectivity ratio of 181 and 146 for the inhibition of DA reuptake and binding to the DAT, respectively.

UI MeSH Term Description Entries
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011955 Receptors, Drug Proteins that bind specific drugs with high affinity and trigger intracellular changes influencing the behavior of cells. Drug receptors are generally thought to be receptors for some endogenous substance not otherwise specified. Drug Receptors,Drug Receptor,Receptor, Drug
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D003042 Cocaine An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake. Cocaine HCl,Cocaine Hydrochloride,HCl, Cocaine,Hydrochloride, Cocaine
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

D Matecka, and R B Rothman, and L Radesca, and B R de Costa, and C M Dersch, and J S Partilla, and A Pert, and J R Glowa, and F H Wojnicki, and K C Rice
December 2008, Neurochemistry international,
D Matecka, and R B Rothman, and L Radesca, and B R de Costa, and C M Dersch, and J S Partilla, and A Pert, and J R Glowa, and F H Wojnicki, and K C Rice
September 2002, Journal of medicinal chemistry,
D Matecka, and R B Rothman, and L Radesca, and B R de Costa, and C M Dersch, and J S Partilla, and A Pert, and J R Glowa, and F H Wojnicki, and K C Rice
September 1999, Journal of medicinal chemistry,
D Matecka, and R B Rothman, and L Radesca, and B R de Costa, and C M Dersch, and J S Partilla, and A Pert, and J R Glowa, and F H Wojnicki, and K C Rice
November 2001, Journal of medicinal chemistry,
D Matecka, and R B Rothman, and L Radesca, and B R de Costa, and C M Dersch, and J S Partilla, and A Pert, and J R Glowa, and F H Wojnicki, and K C Rice
December 2000, Journal of medicinal chemistry,
D Matecka, and R B Rothman, and L Radesca, and B R de Costa, and C M Dersch, and J S Partilla, and A Pert, and J R Glowa, and F H Wojnicki, and K C Rice
March 2002, Journal of medicinal chemistry,
D Matecka, and R B Rothman, and L Radesca, and B R de Costa, and C M Dersch, and J S Partilla, and A Pert, and J R Glowa, and F H Wojnicki, and K C Rice
October 2005, The Journal of pharmacology and experimental therapeutics,
D Matecka, and R B Rothman, and L Radesca, and B R de Costa, and C M Dersch, and J S Partilla, and A Pert, and J R Glowa, and F H Wojnicki, and K C Rice
March 1990, Analytical chemistry,
D Matecka, and R B Rothman, and L Radesca, and B R de Costa, and C M Dersch, and J S Partilla, and A Pert, and J R Glowa, and F H Wojnicki, and K C Rice
April 2003, Journal of medicinal chemistry,
D Matecka, and R B Rothman, and L Radesca, and B R de Costa, and C M Dersch, and J S Partilla, and A Pert, and J R Glowa, and F H Wojnicki, and K C Rice
April 2003, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!